Search

Your search keyword '"Manato Yasuda"' showing total 31 results

Search Constraints

Start Over You searched for: Author "Manato Yasuda" Remove constraint Author: "Manato Yasuda"
31 results on '"Manato Yasuda"'

Search Results

1. Real‐world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis

2. Taste disorders and alopecia in myasthenia gravis

4. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study

5. Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis

6. Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis

8. Recurrent Cerebral Infarcts Associated with Uterine Adenomyosis: Successful Prevention by Surgical Removal

9. Role of soluble forms of follicular helper T-cell membrane molecules in the pathogenesis of myasthenia gravis

10. Minimal symptom expression achievement over time in generalized myasthenia gravis

11. High mobility group box 1 is involved in the pathogenesis of passive transfer myasthenia gravis model

12. Dispersion of mean consecutive differences in single‐fiber electromyography increases diagnostic sensitivity for myasthenia gravis

13. Long-term outcomes and prognostic factors in generalized myasthenia gravis

14. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome

15. Changes in serum complements and their regulators in generalized myasthenia gravis

16. Serum level of soluble urokinase plasminogen activator receptor (suPAR) as a disease severity marker of myasthenia gravis: a pilot study

17. Long‐term prognosis of Japanese Lambert–Eaton myasthenic syndrome patients with or without small‐cell lung carcinoma

18. Marked neurological and immunological improvement in refractory eosinophilic granulomatous polyangiitis after treatment with mepolizumab, an anti‐interleukin‐5 antibody: A case report

19. Propagation of Diffusion-Weighted MRI Abnormalities in the Preclinical Stage of Sporadic Creutzfeldt-Jakob Disease

20. Immunoadsorption apheresis versus intravenous immunoglobulin therapy for exacerbation of myasthenia gravis

21. Serum cytokine and chemokine profiles in patients with immune-mediated necrotizing myopathy

22. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

23. Long-term outcomes and prognostic factors in generalized myasthenia gravis

24. Chronic clicking tinnitus due to palatal tremor: essential or secondary?

25. Roles of cytokines and T cells in the pathogenesis of myasthenia gravis

26. Severe worsening of myasthenic symptoms after the eculizumab discontinuation

27. High levels of serum interleukin-6 are associated with disease activity in myasthenia gravis

29. Increased serum acetylcholine receptor α1 subunit protein in anti-acetylcholine receptor antibody-positive myasthenia gravis

30. Frequency and features of myasthenia gravis developing after thymectomy

31. Efficacy of high-dose intravenous methylprednisolone therapy for ocular myasthenia gravis

Catalog

Books, media, physical & digital resources